Novartis AG’s Zolgensma (onasemnogene abeparvovec) and Kymriah (tisagenlecleucel) have become the first drugs to be approved in South Korea under a new law governing novel regenerative medicines and biologics implemented last August.
All eyes are now on how the products will be treated for reimbursement under the national health insurance (NHI) system...








